Mme Docteur Marina RINAGEL

Bibliographie

• B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

  2021

  ArticleAnnals of the Rheumatic Diseases

• Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients

  2021

  ArticleRheumatology

• Apport de l’écho-doppler pour le diagnostic d’artérite à cellules géantes

  2019

  ArticleLa Presse Médicale

• Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature

  2019

  ArticleAutoimmunity Reviews

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Complications rhumatologiques des inhibiteurs des checkpoints immunitaires

  série de 28 patients, description clinique et prise en charge thérapeutique

  20200

Source : Google Books — filtre catégories médicales/santé/sciences.

Localisation des cabinets

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• SELARL DOCTEUR EMMANUEL SPITZ

  10 RUE NICOLAS THUROT, 67500 Haguenau

  Libéral
  101 m103 m103 m107 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• SELARL DOCTEUR ARNAUD THEULIN

  10 RUE NICOLAS THUROT, 67500 Haguenau

  Libéral
  101 m103 m103 m107 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• HOPITAL DE HAUTEPIERRE

  1 Avenue MOLIERE, 67200 Strasbourg

  ☎ 0388116768Hospitalier🏥 Voir cet établissement
  113 m113 m192 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature

  Autoimmunity reviews · 2019

  📚 76 citations🎯 RCR 5.26Top 7% NIH
• 2

  B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

  Annals of the rheumatic diseases · 2022

  📚 18 citations🎯 RCR 1.14
• 3

  Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients

  Rheumatology (Oxford, England) · 2022

  📚 14 citations🎯 RCR 1.72

  Lire l'abstract Crossref ↓

  Abstract Objective We recently recorded a high prevalence of inclusion body myositis (IBM) in patients with Sjögren’s syndrome (SS). Whether myositis patients with SS differ from myositis patients without SS in terms of the characteristics of the myositis is currently unknown. Anti-cytosolic 5′-nucleotidase 1 A (cN1A) has recently been proposed as a biomarker for IBM but is also frequent in SS. Whether anti-cN1A is independently associated with IBM is still an open question. We aimed to assess the significance of SS and anti-cN1A in myositis patients. Methods Cumulative data on all myositis patients (EULAR/ACR 2017 criteria) screened for SS (ACR/EULAR 2016 criteria) in a single centre were analysed. Ninety-nine patients were included, covering the whole spectrum of EULAR/ACR 2017 myositis subgroups and with a median follow-up of 6 years (range 1.0–37.5). The 34 myositis patients with SS (myositis/SS+) were compared with the 65 myositis patients without SS (myositis/SS-). Results . IBM was present in 24% of the myositis/SS+ patients vs 6% of the myositis/SS- group (P = 0.020). None of the IBM patients responded to treatment, whether they had SS or not. Anti-cN1A was more frequent in myositis/SS+ patients (38% vs 6%, P = 0.0005), independently of the higher prevalence of IBM in this group (multivariate P value: 0.02). Anti-cN1A antibody specificity for IBM was 0.96 (95% CI: 0.87, 0.99) in the myositis/SS- group but dropped to 0.70 (95% CI: 0.48, 0.85) in the myositis/SS+ group. Interpretation In myositis patients, SS is associated with IBM and with anti-cN1A antibodies, independently of the IBM diagnosis. As a consequence, anti-cN1A has limited specificity for IBM in myositis patients with SS.

Publications scientifiques (7) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche